-

Bristol Myers Squibb Announces Dividend

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on August 1, 2025, to stockholders of record at the close of business on July 3, 2025.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on September 2, 2025, to stockholders of record at the close of business on August 5, 2025.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

corporatefinancial-news

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

Industry:

Bristol Myers Squibb

NYSE:BMY
Release Summary
Bristol Myers Squibb Announces Dividend
Release Versions
English

Contacts

Media Relations:
media@bms.com

Investor Relations:
investor.relations@bms.com

More News From Bristol Myers Squibb

U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels

PRINCETON, N.J.--(BUSINESS WIRE)--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels...

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi...

Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025...
Back to Newsroom